Discontinued — last reported Q2 '24
Non-Current Assets
AFS Securities
Royalty Pharma AFS Securities decreased by 2.9% to $406.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 85.8%, from $219.00M to $406.80M. Over 5 years (FY 2020 to FY 2025), AFS Securities shows an upward trend with a 20.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ2 2024
Parent metricTotal investment securities
How to read this metric
An increase reflects capital allocation toward investment portfolios, while a decrease may signal portfolio rebalancing or asset liquidation.
Detailed definition
Available-for-sale securities are debt or equity investments that are not classified as trading or held-to-maturity, and...
Peer comparison
Common in the investment portfolios of banks and insurance companies.
Metric ID:
fin_afs_securitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $202.50M | $188.68M | $204.40M | $239.60M | $63.00M | $339.80M | $226.30M | $267.20M | $343.70M | $353.60M | $437.10M | $473.70M | $629.90M | $657.30M | $693.50M | $219.00M | $271.90M | $302.50M | $419.00M | $406.80M |
| QoQ Change | — | -6.8% | +8.3% | +17.2% | -73.7% | +439.4% | -33.4% | +18.1% | +28.6% | +2.9% | +23.6% | +8.4% | +33.0% | +4.3% | +5.5% | -68.4% | +24.2% | +11.3% | +38.5% | -2.9% |
| YoY Change | — | — | — | — | -68.9% | +80.1% | +10.7% | +11.5% | +445.6% | +4.1% | +93.2% | +77.3% | +83.3% | +85.9% | +58.7% | -53.8% | -56.8% | -54.0% | -39.6% | +85.8% |
Range$63.00M – $693.50M
CAGR+15.8%
Avg YoY Growth+47.7%
Median YoY Growth+35.1%
AFS Securities at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's afs securities?
- Royalty Pharma (RPRX) reported afs securities of $406.80M in Q1 2026.
- How has Royalty Pharma's afs securities changed year-over-year?
- Royalty Pharma's afs securities increased by 85.8% year-over-year, from $219.00M to $406.80M.
- What is the long-term trend for Royalty Pharma's afs securities?
- Over 5 years (2020 to 2025), Royalty Pharma's afs securities has grown at a 20.8% compound annual growth rate (CAGR), from $163.02M to $419.00M.
- What does afs securities mean?
- Investments in securities that are held for potential sale and marked to fair market value.